The ATG5 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with targeted disruption of ATG5 in the HT29 human colorectal adenocarcinoma line. This loss-of-function model enables investigation of autophagy-dependent processes in colorectal cancer. The polyclonal nature provides a heterogeneous genetic background useful for robust functional studies without clonal selection artifacts.
HT29 cells, derived from a human colon adenocarcinoma, display adherent epithelial morphology and are a widely used model for colorectal cancer. They recapitulate intestinal epithelial tumor features, including dysregulated proliferation and metabolic adaptation, making them suitable for studying gene function in colorectal adenocarcinoma. Their well-characterized signaling pathways and response to chemotherapeutic agents provide a relevant context for autophagy research.
ATG5 is a core autophagy protein that conjugates to ATG12 and interacts with ATG16L1, forming a complex essential for LC3 lipidation and autophagosome elongation. Upstream, mTORC1 suppresses and AMPK activates autophagy, while transcription factors TFEB and FoxO regulate ATG5 expression. The ATG5 complex acts downstream of the ULK1 complex (ULK1, ATG13, FIP200, ATG101) and the Class III PI3K complex (Beclin1, VPS34, ATG14). It interacts with ATG7, ATG10, LC3 family proteins (MAP1LC3A/B), and TECPR1. ATG5 drives LC3-II conversion, enabling autophagosome closure and subsequent lysosomal fusion mediated by LAMP1 and RAB7. This promotes p62/SQSTM1-dependent degradation of ubiquitinated cargo, mitophagy, and modulation of apoptosis. Knockout of ATG5 disrupts this cascade, leading to substrate accumulation and compromised stress responses.
In HT29 colorectal cancer cells, ATG5 disruption blocks autophagy-dependent prosurvival signaling, potentially altering drug sensitivity and tumorigenic properties. This model is valuable for studying autophagy??s context-dependent roles in colorectal cancer, including its contributions to proliferation, apoptosis, migration, and resistance to chemotherapy. The model provides a platform to explore how autophagy deficiency influences tumor progression and therapeutic outcomes in a clinically relevant cell background.
Key applications include Western blotting for LC3-II conversion and p62 accumulation, immunofluorescence for LC3 puncta, and autophagy flux assays using lysosomal inhibitors (e.g., chloroquine, bafilomycin A1). Cell viability under nutrient deprivation and apoptosis assays (Annexin V/PI staining) probe stress responses. Chemotherapeutic sensitivity testing with agents such as 5-fluorouracil or oxaliplatin, and migration, invasion, and colony formation assays, evaluate roles in drug resistance and metastatic potential. These tools enable comprehensive dissection of autophagy in colorectal cancer. For further information, please contact Ascent Research.
